This inventor holds 3 USPTO granted patents and 2 published patent applications and 4 EPO patents. Top assignees: Novartis Ag, Xoma Technology Ltd.. Active years: 2012-2015.
Location History:
- Mosaga, CA (US) (2012)
- Moraga, CA (US) (2012 - 2015)
Company Filing History:
3 out of 3,974 
3 out of 84 Years Active: 2012-2015
Title: Innovations in Cancer Treatment by Sharon Lea Aukerman
Introduction
Sharon Lea Aukerman is a notable inventor based in Moraga, CA (US). She has made significant contributions to the field of cancer treatment, holding a total of 3 patents. Her work focuses on innovative methods for treating cancers and pre-malignant conditions, particularly those associated with CD40-expressing cells.
Latest Patents
Aukerman's latest patents include groundbreaking methods for treating human patients with cancer or pre-malignant conditions that are associated with CD40-expressing cells. These methods involve administering anti-CD40 antibodies to patients who are heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). Additionally, her patents provide methods for identifying patients who may benefit from anti-CD40 therapeutic agents, especially those who are refractory to treatment with rituximab (Rituxan®). The methods also include monitoring the efficacy of anti-CD40 antibodies in treating subjects with CD40-expressing cancers.
Career Highlights
Throughout her career, Aukerman has worked with prominent companies in the pharmaceutical industry, including Novartis AG and Xoma Technology Ltd. Her experience in these organizations has contributed to her expertise in developing innovative cancer therapies.
Collaborations
Aukerman has collaborated with notable professionals in her field, including Mohammad Luqman and Bahija Jallal. These collaborations have further enhanced her research and development efforts in cancer treatment.
Conclusion
Sharon Lea Aukerman's innovative work in cancer treatment exemplifies the impact of dedicated inventors in the medical field. Her patents and collaborations continue to pave the way for advancements in therapies for challenging conditions.